IDSA supports COVID-19 vaccine mandates announced by the Occupational Safety and Health Administration for large private employers and the Centers for Medicare and Medicaid Services for employees at Medicare and Medicaid-participating health care facilities.
In recognition of the importance of inclusion, diversity, access and equity as long-term priorities and core values for IDSA, the Society’s Board of Directors recently approved the creation of a permanent IDA&E Committee.
The rise of more transmissible variants of SARS-CoV-2 has spurred growing interest in harnessing information about the genetic sequences of these variants to help treat patients.
To date, 6 million children have been diagnosed with COVID-19. The more than 28 million children who will be eligible to be vaccinated against COVID-19 with this authorization comprise a larger portion of the population than the already eligible 12-17-year-old cohort.
The Infectious Diseases Society of America strongly supports the CDC’s recommendation that unvaccinated people previously infected with the virus that causes COVID-19 get vaccinated as soon as possible after they have fully recovered.
The Infectious Diseases Society of America supports the CDC Advisory Committee on Immunization Practice’s unanimous recommendation to allow “mix-and-match”—or heterologous—COVID-19 booster shots for at-risk populations.
IDSA and HIVMA applaud the bipartisan introduction of the Bolstering Infectious Outbreaks (BIO) Preparedness Workforce Act by Reps. Lori Trahan (D-MA) and David McKinley (R-WV), H.R. 5602, and its inclusion in an Oct. 26 Energy and Commerce Health Subcommittee hearing.
In legal rulings issued on Sept. 1 and Sept. 20, a federal judge in Texas dismissed all claims a group of Lyme disease patients had brought against the Infectious Diseases Society of America.
Infections caused by bacteria resistant to multiple antibiotics led to $1.9 billion in health care costs, more than 400,000 days in the hospital and more than 10,000 deaths among older adults across the U.S. in 2017, according to a new study published today in Clinical Infectious Diseases.
IDSA and the Centers for Disease Control and Prevention have announced they will continue their collaborative effort to support frontline health care professionals caring for patients with COVID-19.
Dr. Collins has provided a steady, scientific voice throughout the COVID-19 pandemic. Under his leadership, NIH was instrumental in researching, developing and communicating about lifesaving COVID-19 vaccines and treatments.
IDSA, PIDS and SHEA recommend, in collaboration with the U.S. Centers for Disease Control and Prevention, that clinicians caring for these evacuees consider the varied presentations of medical conditions, including infectious diseases.